The therapy with anti-epidermal growth factor receptor (anti-EGFR) monoclonal antibodies, which include panitumumab and cetuximab, exhibited to augment the progression-free survival in patients with advanced CRC with wild-type Kirsten rat sarcoma viral oncogene homolog (KRAS) mutations [1,2]. The gene discussed is KRAS; the disease is colorectal carcinoma.